GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies

Key Terms

glp-1 medical

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

fda-approved regulatory

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

qr code technical

A QR code is a square, two‑dimensional barcode that stores information such as a website link, payment details, or product data and can be read instantly by a smartphone camera. For investors it matters because companies use QR codes to drive customer engagement, speed payments, track inventory, or provide instant access to reports and disclosures—similar to a digital shortcut that connects physical items or ads directly to online actions that can affect sales, costs, and transparency.

copay cards financial

A copay card is a coupon-style program offered by drug makers that lowers a patient’s out-of-pocket cost for a prescription, similar to a gift card that covers part of a checkout bill. Investors watch copay cards because they can boost drug sales and patient loyalty by making medicines cheaper for insured people, but they can also affect pricing dynamics, payer negotiations and regulatory or legal risk that may influence a company’s revenue and margins.

regulation fd regulatory

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

Program offers Giant Eagle customers instant access to meaningful savings on brand medications

SANTA MONICA, Calif.--(BUSINESS WIRE)-- GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of RxSmartSaver powered by GoodRx at Giant Eagle pharmacies, giving patients a fast and easy way to access lower prices on high-cost brand medications directly at the pharmacy counter.

“We are excited to partner with Giant Eagle to make brand medications more affordable and easier to access for the many patients who rely on them,” said David Graziano, Head of Retail Network at GoodRx. “By integrating savings directly into the pharmacy experience and keeping the process simple for both pharmacy staff and patients, we help pharmacies better support their communities while strengthening their economics. Expanding access to brand medications is a win for consumers, pharmacies, and manufacturers.”

Launched earlier this year, RxSmartSaver is a turnkey solution that allows patients to instantly unlock meaningful savings on brand medications that are often not covered by insurance or come with high out-of-pocket costs. Through the program, Giant Eagle Pharmacy customers can access a wide range of affordability options, including manufacturer copay cards and nearly 80 unique cash prices across high-cost brand medications, including Farxiga® and Repatha®. Popular FDA-approved GLP-1 medications are also available at discounted cash prices, including Ozempic® and Wegovy® injections for $199 per month, and the new Wegovy® pill for $149 per month.

Patients simply scan a QR code at the pharmacy counter using their smartphone, enter the RxSmartSaver portal, and present the available savings to the pharmacist at checkout. The experience is designed to require no operational lift for pharmacy staff, while providing immediate, tangible help for patients facing high prescription costs.

“At Giant Eagle Pharmacy, we are committed to ensuring our patients can access the medications they need to live healthier lives,” said Mike Chappell, Senior Vice President of Pharmacy at Giant Eagle. “Working with GoodRx to bring RxSmartSaver to Giant Eagle Pharmacy reinforces our dedication to providing convenient and affordable care, while supporting our pharmacists with another opportunity to help patients realize meaningful savings on their prescription medications.”

The introduction of RxSmartSaver builds on GoodRx’s broader efforts to support retail pharmacies by helping them improve profitability, reduce prescription abandonment, and drive innovation in the prescription experience. By making affordability tools readily accessible at the point of dispensing, the program helps Giant Eagle stores reduce prescription abandonment, streamline workflows, and deepen patient relationships. GoodRx is ultimately improving the patient experience while delivering stronger economics for retail pharmacy partners.

RxSmartSaver is now available across more than 200 Giant Eagle pharmacies throughout Indiana, Maryland, Ohio, Pennsylvania, and West Virginia.

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $85 billion on the cost of their medications.

​GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits to the Company related to the Giant Eagle relationship. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260108363426/en/

Media Contact

press@goodrx.com

Source: GoodRx